Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroendocrine Tumors × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 88 Carcinoma, Intraductal, Noninfiltrating 11 Breast Carcinoma In Situ 9 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Breast Neoplasms, Male 6 Neoplasms 5 Glioblastoma 4 Central Nervous System Neoplasms 4 Inflammatory Breast Neoplasms 3 Gliosarcoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Glioma 2 Fallopian Tube Neoplasms 2 Breast Cancer Female 2 Brain Neoplasms 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Risk Reduction Behavior 1 Recurrence 1 Premenopausal Breast Cancer 1 Oligodendroglioma 1 Non Metastatic Breast Cancer 1 Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1 Neuroendocrine Tumors 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

lutetium Lu 177 dotatate 15 Everolimus 10 Temozolomide 9 Nivolumab 8 Capecitabine 7 pembrolizumab 6 cabozantinib 5 Sunitinib 5 lanreotide 4 gallium Ga 68 dotatate 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 lenvatinib 3 avelumab 3 Octreotide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Injections 3 Etoposide 3 Cyclophosphamide 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2 Specimen Handling 2 Positron Emission Tomography Computed Tomography 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡